Karyopharm Therapeutics Inc. (KPTI) AI Stock Analysis

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of drugs targeting nuclear export mechanisms to treat cancer and other diseases. Its approach centers on Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the XPO1 nuclear export protein. The company's flagship product, XPOVIO, is approved for multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has partnered with the Menarini Group to develop and commercialize NEXPOVIO in Europe, the United Kingdom, Latin America, and other regions, while continuing to advance oral SINE compounds to enhance nuclear accumulation of tumor suppressor proteins.

Karyopharm's annual revenue rose from $145.2M in FY2024 to $146.1M in FY2025, reflecting 0.6% growth, after declining from $209.8M in FY2021. Gross margins have remained consistently high, registering at 95.9% in FY2025. However, net losses expanded to -$196.0M in FY2025, compared to -$76.4M in FY2024, driven partly by $125.6M in research and development expenses. Over the trailing twelve months, revenue was $146.6M with an operating margin of -67.4% and an EPS of -$14.33. For the latest quarter ended June 30, 2026, quarterly revenue fell 11.9% year-over-year.

As of June 30, 2026, Karyopharm held $65.1M in cash and short-term investments against total debt of $215.9M, resulting in net debt of $150.8M. The company faces a current ratio of 0.79 and negative shareholders' equity of -$330.2M against total assets of $111.3M. Cash generation remains negative, with free cash flow of -$75.4M and operating cash flow of -$75.4M in FY2025. Dilution has been significant, with the 5-year share count increasing by 399.6%.

Karyopharm trades at a price-to-sales multiple of 0.1x, below the 4.1x median of its US-listed Healthcare peers. Its enterprise value-to-revenue ratio sits at 1.6x, while price-to-book is 12.0x. The company has experienced sharp price declines, with a 1-year return of -93.5% and a 5-year return of -99.5%, trailing the S&P 500 (SPY) returns of 16.8% and 83.0% over the respective periods. The stock closed at $0.39 on October 16, 2026, standing 93.9% below its 200-day average.

Wall Street coverage includes 2 Strong Buy, 2 Buy, and 1 Hold ratings. The mean price target is $7.25, representing a 1759.0% upside compared to the last close of $0.39. For the fiscal year ending December 31, 2026, analysts estimate revenue of $135.6M and an EPS of -$5.84. Over the last four quarters, Karyopharm beat EPS estimates 1 time. The next earnings date is scheduled for November 2, 2026.

This page is an AI-written research summary of Karyopharm Therapeutics Inc. (KPTI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KPTI income statement, KPTI balance sheet, KPTI key metrics, KPTI analyst forecast, KPTI chart. See the KPTI stock overview for the latest quote and news.